A Safety and Immunogenicity Trial of IHV01

HIV Infection Clinical Trial

— FLSC-001  

Official title:

A Phase I Safety and Immunogenicity Trial of IHV01 in HIV-1 Uninfected Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02756208
• Other study ID #: HP-00065547
• Status: Completed
• Phase: Phase 1
• Start date: November 2015
• Est. completion date: July 2018

Study information

• Verified date: November 2021
• Source: University of Maryland, Baltimore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1 uninfected).

Description:

This is a Phase 1 randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers who are Human Immunodeficiency Virus-1 (HIV-1) uninfected. Participants in the study will receive 4 injections at 0, 4, 8 and 24 weeks and will be followed for an additional 24 weeks. The total study duration will be 48 weeks. As this is a Phase 1 trial, the primary objective is to document safety of the Full Length Single Chain (FLSC) gp120-CD4 complex vaccine with a secondary objective to evaluate immune responses induced by the vaccine. This vaccine is being evaluated as it is constructed so that the gp120 and CD4 moieties form a stable intra-chain binding interaction that forms a transition state structure that presents conserved, conformational domains involved in the early HIV replication process. It is hypothesized that antibodies directed to these epitopes would be highly cross-reactive and potentially useful for HIV vaccine development.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: July 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Age: 18 to 45 years of age.

2. Sex: Male or Female (female volunteers of child bearing potential must have a negative serum beta human chorionic gonadotropin (b-HCG or pregnancy) test at time of screening and entry into the study and provide assurance of the use of effective(as judged by the investigator) birth control methods or abstinence beginning at least 60 days prior to the study and during the study

3. Documented HIV-1 negative by ELISA

4. Be in good general health without clinically significant medical history, physical examination findings, or clinically significant abnormal laboratory results (i.e., chronic medical conditions as noted in the exclusion criteria such as cancer as well as any conditions that in the opinion of the investigator might pose a risk to the volunteer)

5. No identifiable risk factor for acquisition of HIV infection (i.e., intravenous drug use/needle sharing, unprotected sex with multiple partners)

6. Negative b-HCG pregnancy test on the day of initial vaccination.

7. Negative screen for Hepatitis B surface antigen (HBsAg);

8. Negative screen for antibodies to Hepatitis C virus (Patient may enroll if patient can provide documentation of negative hepatitis C viral load.)

9. Participant must have a CD4 count ( a type of white blood cells) within the normal range of the clinical laboratory utilized for the study and a CD4 percentage within 20% of the normal range of the clinical laboratory

10. Laboratory parameters must be within pre-specified limits as defined by exclusion criteria.

11. Volunteers must be willing and able to provide written informed consent to participate in the study.

12. Available for at least 48 weeks of follow-up.

Exclusion Criteria:

1. High risk behavior for acquisition of HIV within 24 weeks of study entry(i.e., intravenous drug use/needle sharing, unprotected sex with multiple partners)

2. Volunteers with an acute and clinically significant medical event (as determined by the investigator) within the past 30 days of screening.

3. Have active tuberculosis or other systemic infectious process by review of systems and physical examination

4. Have a history of immunodeficiency, autoimmune disease, or use of immunosuppressive medications

5. Current treatment for malignancy other than basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix

6. Is pregnant

7. History of any chronic illness that would interfere with conduct or completion of study(as determined by the investigator)

8. Have evidence of psychiatric, medical and/or substance abuse problems during the past 24 weeks that the investigator believes would adversely affect the volunteer's ability to participate in the trial

9. Have occupational or other responsibilities that would prevent completion of participation in the study

10. Have received any live, attenuated vaccine except rabies vaccine within 60 days of study entry

11. Vaccine (FDA approved; e.g. influenza, pneumovax, etc) administration within 30 days of immunization with the study vaccine. NOTE: Medically indicated subunit or killed vaccines (e.g., Hepatitis A or Hepatitis B) should be given prior to trial initiation or after completion of the study immunizations. If patient requires immunization, injections should be given more than 2 weeks prior or 2 weeks after study immunization

12. Have used experimental therapeutic agents within 30 days of study entry

13. Have received blood products or immunoglobulins in the past 12 weeks

14. Have a history of anaphylaxis or other serious adverse reactions to vaccines

15. Have previously received an HIV vaccine

16. Volunteers with any of the following laboratory parameters at the screening visit (within 30 days of immunization): Hemoglobin <10 (without having received a blood or red blood cell transfusion within 30 days prior to laboratory test); neutrophil count <750 cells/mm3; platelet count <50,000/mm3; serum creatinine > 2.0 mg/dL; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limits of normal; total bilirubin > 1.5 mg/dL

17. Pregnant women or women who are breast-feeding; female volunteers of childbearing potential who are not using or willing to use an effective (as judged by the investigator) barrier contraceptive methods or abstinence while enrolled in this study.

18. Use of any immune modulators or suppressors within 45 days of study entry including but not limited to agents such as interleukins (e.g. IL-2), interferons (e.g. IFN-*), high dose systemic steroids (e.g. = 20 mg prednisone equivalent/day) for > 30 days, thalidomide, filgrastim (G-CSF), sargramostim (GM-CSF), dinitrochlorobenzene (DNCB), thymosin alpha, thymopentin, inosiplex, polyribonucleoside, ditiocarb sodium, cyclosporin, mycophenolate mofetil, methotrexate, and cancer chemotherapy.

19. No other investigational agent within 30 days of study entry

20. Any other condition which, in the opinion of the investigator, might interfere with completion of the study or evaluation of the results

21. Have active Hepatitis B virus infection (positive HBsAg) or Hepatitis C infection(defined as positive antibodies)

Related Conditions & MeSH terms

• HIV Infection
• HIV Infections

Intervention

Biological:
• 300 ug FLSC vaccine
FLSC vaccine 300 ug (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
• 150 ug FLSC vaccine
FLSC vaccine 150 ug (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
• 75 ug FLSC vaccine
FLSC vaccine 75 ug (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
• Placebo
Placebo sterile saline (0.25 - 1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168

Locations

Country	Name	City	State
United States	University of Maryland, Institute of Human Virology	Baltimore	Maryland

Sponsors (3)

Lead Sponsor	Collaborator
University of Maryland, Baltimore	Auro Vaccines LLC, Bill and Melinda Gates Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Local and Systemic Reactogenicity Signs and Symptoms	Signs and symptoms include pain, tenderness, maximum severity of pain and/or tenderness, erythema, induration, fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms.	48 weeks
Primary	Number of Participants With Related Adverse Events	Treatment emergent adverse events assessed by investigator to be either possibly, probably, or definitely related to study treatment. Medical Dictionary for Regulatory Activities (MedDRA) preferred term, severity, and assessed relationship to study products.	48 weeks
Primary	Number of Participants With Sustained Decrease in CD4 Count and CD4%.	CD4 count was monitored from baseline and at each study visit through study completion. Baseline CD4 and CD4% levels were calculated by taking the average of the screening and first vaccination visits. The number of individuals who had sustained (2 consecutive time points) 30% decrease in CD4 cell/ul and CD4% from baseline were counted.	48 weeks
Secondary	Binding Antibody Response Rates to FLSC	Percent of participants with anti-FLSC antibodies as assessed by ELISA by 2 weeks after final vaccination	2 weeks after 4th (last) vaccination.
Secondary	Binding Antibody Response Rates to BaL-gp120	Percent of participants with anti-gp120 antibodies as assessed by ELISA	2 weeks after 4th (last) vaccination
Secondary	Competitive Antibody Rates to CD4i Epitopes	Percent of participants with antibodies competing with A32 or 17b as assessed by ELISA.	2 weeks after 4th (last) vaccination